Overview

Stelara fOr ChRonic AntibioTic rEfractory pouchitiS

Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of ustekinumab in the treatment of chronic antibiotic refractory and relapsing pouchitis.
Phase:
Phase 3
Details
Lead Sponsor:
Universitaire Ziekenhuizen Leuven
Collaborator:
Janssen, LP
Treatments:
Anti-Bacterial Agents
Antibiotics, Antitubercular
Ustekinumab